阿斯利康因考虑美国市场增长及政府政策,计划从美国上市并可能变更总部。其药物被英国NHS拒绝后,公司市值约2200亿美元,此举将对伦敦交易所造成重大打击,引发英国政府可能采取措施阻止。
Source Link阿斯利康因考虑美国市场增长及政府政策,计划从美国上市并可能变更总部。其药物被英国NHS拒绝后,公司市值约2200亿美元,此举将对伦敦交易所造成重大打击,引发英国政府可能采取措施阻止。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.